Table of Content

1. Key Insights

2. Executive Summary of BRAF NSCLC Epidemiology

3. BRAF Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
3.1. Introduction
3.1.1. Cellular Classification of NSCLC
3.1.2. Signs and Symptoms of NSCLC
3.1.3. Risk Factors of Lung Cancer
3.1.4. Causes of NSCLC
3.1.5. Disease Biology: NSCLC

4. Diagnosis of NSCLC
4.1. Diagnostic Algorithm for NSCLC
4.2. Stages of NSCLC
4.3. Staging System

5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Total Incident cases of NSCLC patients in the 7MM
5.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
5.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
5.4. The United States Epidemiology
5.4.1. Total Incident cases of NSCLC patients in the United States
5.4.2. Total Incident cases of NSCLC patients by Histology in the United States
5.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
5.4.4. Total Incident cases of BRAF Mutated NSCLC in the United States

6. EU-5 Epidemiology
6.1. Germany
6.1.1. Total Incident cases of NSCLC patients in Germany
6.1.2. Total Incident cases of NSCLC patients by Histology in Germany
6.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
6.1.4. Total Incident cases of BRAF Mutated NSCLC in Germany
6.2. France
6.2.1. Total Incident cases of NSCLC patients in France
6.2.2. Total Incident cases of NSCLC patients by Histology in France
6.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
6.2.4. Total Incident cases of BRAF Mutated NSCLC in France
6.3. Italy
6.3.1. Total Incident cases of NSCLC patients in Italy
6.3.2. Total Incident cases of NSCLC patients by Histology in Italy
6.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
6.3.4. Total Incident cases of BRAF Mutated NSCLC in Italy
6.4. Spain
6.4.1. Total Incident cases of NSCLC patients in Spain
6.4.2. Total Incident cases of NSCLC patients by Histology in Spain
6.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
6.4.4. Total Incident cases of BRAF Mutated NSCLC in Spain
6.5. The United Kingdom
6.5.1. Total Incident cases of NSCLC patients in the United Kingdom
6.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
6.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
6.5.4. Total Incident cases of BRAF Mutated NSCLC in the United Kingdom

7. Japan Epidemiology
7.1. Japan
7.1.1. Total Incident cases of NSCLC patients in Japan
7.1.2. Total Incident cases of NSCLC patients by Histology in Japan
7.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
7.1.4. Total Incident cases of BRAF Mutated NSCLC in Japan

8. Appendix
8.1. Bibliography

9. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight



List of Figures


Figure 1 BRAF NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total Incident cases of BRAF Mutated NSCLC in the United States (2017–2030)
Figure 22 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 23 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 24 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 25 Total Incident cases of BRAF Mutated NSCLC in Germany (2017–2030)
Figure 26 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 27 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 28 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 29 Total Incident cases of BRAF Mutated NSCLC in France (2017–2030)
Figure 30 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 31 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 32 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 33 Total Incident cases of BRAF Mutated NSCLC in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 35 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 36 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 37 Total Incident cases of BRAF Mutated NSCLC in Spain (2017–2030)
Figure 38 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 41 Total Incident cases of BRAF Mutated NSCLC in the United Kingdom (2017–2030)
Figure 42 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 43 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 44 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 45 Total Incident cases of BRAF Mutated NSCLC in Japan (2017–2030)

 

List of Tables


Table 1 Summary of BRAF Non-small-cell Lung Cancer (NSCLC) Epidemiology and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total Incident cases of BRAF Mutated NSCLC in the United States (2017–2030)
Table 10 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 11 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 12 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 13 Total Incident cases of BRAF Mutated NSCLC in Germany (2017–2030)
Table 14 Total Incident cases of NSCLC patients in France (2017–2030)
Table 15 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 16 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 17 Total Incident cases of BRAF Mutated NSCLC in France (2017–2030)
Table 18 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 19 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 20 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 21 Total Incident cases of BRAF Mutated NSCLC in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 23 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 24 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 25 Total Incident cases of BRAF Mutated NSCLC in Spain (2017–2030)
Table 26 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 29 Total Incident cases of BRAF Mutated NSCLC in the United Kingdom (2017–2030)
Table 30 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 31 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 32 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 33 Total Incident cases of BRAF Mutated NSCLC in Japan (2017–2030)